Blood filtration company ExThera Medical disclosed on Tuesday that critically ill patients treated with its Seraph 100 Microbind Affinity Blood Filter within 60 hours of ICU admission experienced a survival rate double over patients treated in the ICU after 60 or more hours.

Based on the company's new study and new findings published in Nephrology Dialysis Transplantation, the survivability in ICU COVID patients that started Seraph 100 treatment within 60 hours of ICU admission was 65.5% while it was 37.5% in patients that started the treatment after more than 60 hours in the ICU.

According to the company, the Seraph 100 is the first blood purification device to be shown to reduce both bacterial and viral loads in the bloodstream and has been used on more than 800 US and EU patients with COVID-19 since April 2020.

The company's Seraph 100 received the CE mark for the reduction of bloodstream pathogens in EU in 2019 and the US FDA's Authorization for Emergency Use for use in patients with COVID-19 admitted to the ICU with confirmed or imminent respiratory failure in April 2020.

ExThera Medical added that the study is called a Multicentre Evaluation of Blood Purification with the company's Seraph 100 Microbind Affinity Blood Filter for the Treatment of Severe COVID-19: A Preliminary Report (2021). The Interim-analysis of the COSA (COVID-19 patients treated with the Seraph 100 Microbind Affinity filter) registry, Nephrology Dialysis Transplantation 2021.